Concord Wealth Partners United Therapeutics Corp Transaction History

Concord Wealth Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$174.81 - $241.14 $29,018 - $40,029	-166 Reduced 91.71%	15 $4,000
Q1 2022 Apr 20, 2022	SELL	$166.16 - $213.96 $17,612 - $22,679	-106 Reduced 36.93%	181 $32,000
Q4 2021 Jan 21, 2022	BUY	$184.32 - $216.08 $44,605 - $52,291	242 Added 537.78%	287 $62,000
Q3 2021 Nov 09, 2021	SELL	$179.86 - $214.88 $2,338 - $2,793	-13 Reduced 22.41%	45 $8,000
Q2 2021 Jul 29, 2021	BUY	$170.47 - $211.93 $7,330 - $9,112	43 Added 286.67%	58 $10,000
Q1 2021 May 13, 2021	BUY	$153.94 - $174.85 $2,309 - $2,622	15 New	15 $3,000

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.